Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target ...

Analyst Gena Wang of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

Capricor Therapeutics (NASDAQ:CAPR) stock rose 5% in midday trading Friday after the company reported positive long-term data ...

On Thursday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $122.41 which represents a slight increase of $4.42 or 3.75% from the prior close of $117.99. The stock opened ...

Supporters of the Arkansas Voter Integrity Initiative filed nine lawsuits and only won two, both of which could still be ...

The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...

Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...

Two Chinese biotechs are testing CRISPR gene editing in boys with muscular dystrophy, even as projects at U.S. companies like ...

In the last week, the United States market has stayed flat, yet it has risen by 30% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high ...

Originally published in Quest Diagnostics' 2023 Corporate Responsibility Report We continued to grow access to and ...

Recent Transaction Overview On September 30, 2024, Ikarian Capital, LLC (Trades, Portfolio) made a significant adjustment to ...